Ready-to-use therapeutics, real patient impact
Xeris Biopharma (xerispharma.com) earns a Brand Analyzer score of 73 out of 100, placing it in the Brand-Ready tier among Healthcare brands. Among 3448 Healthcare brands analyzed, Xeris Biopharma ranks in the 55th percentile (category average 72, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 82/100, Digital Presence 94/100, Visual Identity 96/100, Messaging Clarity 100/100, Trust Foundation 87/100, AI Discoverability 57/100, Brand Authority 16/100.
Xeris Biopharma (NASDAQ: XERS), operating as Xeris Pharmaceuticals, is a biopharmaceutical company focused on developing and commercializing ready-to-use therapeutic medicines. Its portfolio includes the first FDA-approved autoinjector for severe hypoglycemia, along with treatments for endogenous Cushing's syndrome and primary or secondary periodic paralysis. The company targets patients with these conditions and the healthcare providers who treat them, positioning itself as a growth-oriented biopharmaceutical company using advanced delivery technologies to address unmet medical needs.
| Brand Name | Xeris Biopharma |
|---|---|
| Domain | xerispharma.com |
| Industry | Healthcare |
| Main Competitors | Eli Lilly (78/100), Novo Nordisk (88/100), Amphastar Pharmaceuticals (66/100), Corcept Therapeutics (81/100), Recordati (75/100), Zealand Pharma (77/100) |
Moz Domain Authority 41/100 vs category average 35 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,061,899 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Xeris Pharmaceuticals (XERS) improves patient lives by developing and commercializing innovative, ready-to-use therapeutic medicine." (Meta description: 14 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Drupal.
Social footprint: verified profiles on LinkedIn, Instagram, X (Twitter); no detected presence on Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Xeris Biopharma scores 19/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Xeris Biopharma has a weak AI-visibility profile at 19/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (43/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #1,061,899 (Tranco), a Moz Domain Authority of 41/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and thin schema.org structured data. In a live check, Claude could already identify Xeris Biopharma from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Xeris Biopharma?", Claude could identify the brand as of August 2026. Xeris Biopharma is a specialty pharmaceutical company that develops and markets ready-to-use injectable and infusion therapies, using its proprietary formulation technologies to create alternatives to drugs that traditionally require reconstitution. Its key products include Gvoke Best known for Gvoke, a ready-to-use liquid glucagon injection for treating severe hypoglycemia without reconstitution.
When asked "Best brands similar to Xeris Biopharma?", Claude would recommend Xeris Biopharma as of August 2026. It's a legitimate and notable name in specialty pharma, particularly recognized for innovation in ready-to-use injectable therapies like its glucagon product.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Xeris Biopharma's main competitors include Eli Lilly (78/100), Novo Nordisk (88/100), Amphastar Pharmaceuticals, Corcept Therapeutics (81/100), Recordati. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Xeris Biopharma and Novo Nordisk are competitors in Healthcare. Brand Analyzer scores Xeris Biopharma at 73/100 and Novo Nordisk at 88/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Xeris Biopharma include Eli Lilly (78/100), Novo Nordisk (88/100), Amphastar Pharmaceuticals, Corcept Therapeutics (81/100), Recordati. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Xeris Biopharma has low AI-search visibility, scoring 19/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 29, recommendation 43). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Xeris Biopharma official site
Xeris Biopharma offers a diversified portfolio of ready-to-use therapeutic products, including the first FDA-approved autoinjector for severe hypoglycemia. Its offerings also address endogenous Cushing's syndrome and primary or secondary periodic paralysis, using advanced delivery technologies designed to simplify administration for patients and healthcare providers.
Sources: Xeris Biopharma official site
Xeris Biopharma scores 43/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Xeris Biopharma official site
Xeris Biopharma, operating under the name Xeris Pharmaceuticals (NASDAQ: XERS), is a biopharmaceutical company that develops and commercializes innovative, ready-to-use therapeutic medicines. It focuses on advanced drug delivery technologies designed to simplify treatment for patients with specific, often urgent, medical needs.
Sources: Xeris Biopharma official site
Xeris Biopharma develops and commercializes ready-to-use therapeutic products, including an FDA-approved autoinjector for severe hypoglycemia. The company also provides treatments addressing endogenous Cushing's syndrome and primary or secondary periodic paralysis, aiming to improve patient outcomes through advanced delivery technologies.
Sources: Xeris Biopharma official site
Xeris Biopharma can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Xeris Biopharma official site
Xeris Biopharma's products are used by patients with severe hypoglycemia, endogenous Cushing's syndrome, and primary or secondary periodic paralysis, as well as the healthcare providers who diagnose and treat these conditions.
Sources: Xeris Biopharma official site
Xeris Biopharma is known for developing the first FDA-approved autoinjector for severe hypoglycemia, a ready-to-use therapeutic delivery innovation. It is also recognized for its broader portfolio addressing conditions such as endogenous Cushing's syndrome and periodic paralysis using advanced, ready-to-use drug delivery technologies.
Sources: Xeris Biopharma official site
Ranked closest to Xeris Biopharma: World Veterinary Association (73/100), Workplace Integra (73/100), Zion HealthShare (73/100), Zuri Health (73/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zimmer Biomet (81/100).
Category leader: Elsevier (96/100).